<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00104741</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000416088</org_study_id>
    <secondary_id>FRE-FNCLCC-GETUG-14/0207</secondary_id>
    <secondary_id>EU-20503</secondary_id>
    <nct_id>NCT00104741</nct_id>
  </id_info>
  <brief_title>Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer</brief_title>
  <official_title>Multicentre Randomized Trial Assessing the Efficacy of a Short Neoadjuvant and Concomitant Hormone Therapy to an Exclusive Curative Cornformational Radiotherapy of Locolized Prostate Cancer With Intermediate Prognosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as
      triptorelin and flutamide, may stop the adrenal glands from making androgens. Radiation
      therapy uses high-energy x-rays to kill tumor cells. Giving triptorelin and flutamide
      together with radiation therapy may be an effective treatment for prostate cancer. It is not
      yet known whether giving triptorelin and flutamide together with external-beam radiation
      therapy is more effective than external-beam radiation therapy alone in treating prostate
      cancer.

      PURPOSE: This randomized phase III trial is studying triptorelin, flutamide, and
      external-beam radiation therapy to see how well they work compared to external-beam radiation
      therapy alone in treating patients with stage II or stage III prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the impact of neoadjuvant androgen blockade therapy comprising triptorelin and
           flutamide followed by conformal external beam radiotherapy and continued androgen
           blockage therapy vs conformal external beam radiotherapy alone in patients with stage II
           or III prostate cancer.

        -  Compare the survival rate, in terms of 5-year clinical or biological remission, in
           patients treated with these regimens.

        -  Compare overall survival in patients treated with these regimens.

        -  Compare acute and late toxicity of these regimens in these patients.

        -  Compare quality of life of patients treated with these regimens.

        -  Determine the value and time-delay to obtain prostate-specific antigen nadir in patients
           treated with external beam radiotherapy alone.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment
      arms.

        -  Arm I: Patients undergo conformal external beam radiotherapy.

        -  Arm II: Patients receive androgen blockade therapy comprising triptorelin subcutaneously
           every 4 weeks and oral flutamide once daily. Androgen blockade therapy continues for a
           total of 4 months. Two months after initiation of androgen blockade therapy, patients
           undergo conformal external beam radiotherapy.

      Quality of life is assessed.

      PROJECTED ACCRUAL: A total of 450 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2004</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of complete androgen blockade for 4 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival, in terms of clinical or biological remission, at 5 years</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute and late toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Value and time-delay to obtain prostate-specific antigen nadir (for patients undergoing external beam radiotherapy alone)</measure>
  </primary_outcome>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flutamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triptorelin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed prostate cancer, meeting the following clinical staging
             criteria:

               -  Stage T1b-T1c AND prostate specific antigen (PSA) ≥ 10 ng/mL OR Stage T1b-T1c AND
                  Gleason score ≥ 7 OR Stage T2a-T3a

               -  No lymph node invasion (N0 or N-)

                    -  Patients with ≥ 10% risk by the Partin table must undergo curage

               -  No metastatic disease (M0) by thoracic radiography and bone scan

          -  PSA &lt; 30 ng/mL

          -  No history of invasive cancer

        PATIENT CHARACTERISTICS:

        Age

          -  Under 75

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  At least 10 years

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  No prior hormonal therapy

        Radiotherapy

          -  No prior pelvic radiotherapy

        Surgery

          -  No prior radical prostatectomy

          -  No prior castration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard M. Dubray, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Henri Becquerel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique De Rochebelle</name>
      <address>
        <city>Ales</city>
        <zip>F-30100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Cretin</last_name>
      <phone>33-4-6654-2110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84082</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Chauvet, MD</last_name>
      <phone>33-4-9027-6182</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Pasteur</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>33-03-89-12-4102</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>33-3-8912-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Leon Lagrange, MD</last_name>
      <phone>33-1-49-814-524</phone>
      <email>jean-leon.lagrange@hmn.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Intercommunal De Creteil</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Martin, MD</last_name>
      <phone>33-1-45-17-52-10</phone>
      <email>michel.martin@chicreteil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Monnet</name>
      <address>
        <city>Epinal</city>
        <zip>88021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Aubertel</last_name>
      <phone>33-3-2968-7020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal des Alpes du Sud</name>
      <address>
        <city>Gap</city>
        <zip>05007</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdellatif Zribi, MD</last_name>
      <phone>33-4-9240-6785</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Lartigau, MD, PhD</last_name>
      <phone>33-3-2029-5911</phone>
      <email>e-lartigau@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Regional Universitaire de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Clavere, MD</last_name>
      <phone>33-5-5505-6268</phone>
      <email>pierre.clavere@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Pommier, MD</last_name>
      <phone>33-4-7878-2648</phone>
      <email>pommier@lyon.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>33-91-22-37-00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact person</last_name>
      <phone>33-91-385-708</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Bernard Dubois, MD</last_name>
      <phone>33-4-6761-3100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68051</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>33-3-8964-7522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Grandgirard</last_name>
      <phone>33-3-8964-7522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Regional Rene Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Bourdin, MD</last_name>
      <phone>33-2-4067-9900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06088</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. M. Hannoun-Levi, MD</last_name>
      <phone>33-4-9203-1260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique De Valdegour</name>
      <address>
        <city>Nimes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Cretin, MD</last_name>
      <phone>33-46-662-58-02</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital d'Instruction des Armees du Val de Grace</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryse Fayolle-Campana</last_name>
      <phone>33-1-4051-4558</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Hennequin, PhD</last_name>
      <phone>33-1-4249-4949</phone>
      <email>christophe.hennequin@sls.ap-hop-paris.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Simon</last_name>
      <phone>33-142-178-174</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francoise Pene, MD</last_name>
      <phone>33-1-5601-6562</phone>
      <email>francoisepene@tnn.aphp.paris.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>33-4-78-86-11-58</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>33-549-444-538</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tan Dat Nguyen, MD</last_name>
      <phone>33-03-2650-4351</phone>
      <email>tandat.nguyen@reims.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35064</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Le Prise, MD</last_name>
      <phone>33-2-9925-3000</phone>
      <email>elptrennes@fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard M. Dubray, MD, PhD</last_name>
      <phone>33-232-082-262</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Bachaud, MD</last_name>
      <phone>33-5-6142-4242</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Bretonneau de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Le Floch, MD</last_name>
      <phone>33-2-4747-4776</phone>
      <email>lefloch@med.univ-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>33-3-8359-8400</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2005</study_first_submitted>
  <study_first_submitted_qc>March 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2005</study_first_posted>
  <last_update_submitted>February 18, 2011</last_update_submitted>
  <last_update_submitted_qc>February 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2011</last_update_posted>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Flutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

